Novartis Ag (NVSEF) Intangibles (2009 - 2026)
Novartis Ag's (NVSEF) quarterly Intangibles came in at $10.6 billion in Q1 2026, down 63.96% quarter-over-quarter from $29.4 billion in Q4 2025.
Novartis Ag (NVSEF) Intangibles (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Intangibles across 12 years of filings, most recently posting $10.6 billion for Q1 2026.
- Intangibles for Q1 2026 came in at $10.6 billion, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $10.6 billion (changed N/A YoY), and the FY2025 annual result was $29.4 billion, up 9.27% from the prior year.
- Intangibles came in at $10.6 billion for Q1 2026 at Novartis Ag, down from $29.4 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $58.3 billion in Q4 2023 to a low of -$2.6 billion in Q4 2022.
- The 5-year median for Intangibles is $26.9 billion (2024), against an average of $19.1 billion.
- Across the five-year window, Intangibles surged 2667.09% in 2023 and slumped 53.85% in 2024, its largest moves.
- Novartis Ag's Intangibles stood at -$2.6 billion in 2022, then soared by 2314.93% to $58.3 billion in 2023, then plunged by 53.85% to $26.9 billion in 2024, then advanced by 9.27% to $29.4 billion in 2025, then sank by 63.96% to $10.6 billion in 2026.
- The last three Intangibles figures came in at $10.6 billion (Q1 2026), $29.4 billion (Q4 2025), and $29.2 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Novartis Ag | - | - | - | 10.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.60 Bn |
| Dec 31, 2025 | 29.41 Bn |
| Jun 30, 2025 | 29.24 Bn |
| Dec 31, 2024 | 26.92 Bn |
| Jun 30, 2024 | 27.78 Bn |
| Mar 31, 2024 | 286.00 Mn |
| Dec 31, 2023 | 58.32 Bn |
| Jun 30, 2023 | 28.00 Bn |
| Dec 31, 2022 | -2.63 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 901.00 Mn |
| Dec 31, 2021 | -2.41 Bn |
| Sep 30, 2021 | 307.00 Mn |
| Jun 30, 2021 | 145.00 Mn |
| Mar 31, 2021 | 123.00 Mn |
| Dec 31, 2020 | -26.57 Bn |
| Jun 30, 2020 | 7.57 Bn |
| Dec 31, 2019 | 7.43 Bn |
| Jun 30, 2019 | 411.00 Mn |
| Mar 31, 2019 | 505.00 Mn |